[논문]Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients

Saeedi, Ramesh; Johns, Kevin; Frohlich, Jiri; Bennett, Matthew T.; Bondy, Gregory

doi:10.1186/s12944-015-0054-x

Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients 원문보기

Lipids in health and disease, v.14, 2015년, pp.57 -

Saeedi, Ramesh (Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, Canada) , Johns, Kevin (Experimental Medicine Program, Faculty of Medicine, University of British Columbia, Vancouver, Canada) , Frohlich, Jiri (Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, Canada) , Bennett, Matthew T. (Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, Canada) , Bondy, Gregory (Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, Canada)

Abstract ▼ AI-Helper

BackgroundHIV-infected patients on antiretroviral therapy frequently develop dyslipidemias and, despite therapy with potent lipid-lowering agents, a high percentage does not achieve guideline recommended lipid targets. In this study, we examined the efficacy of combination treatment with a statin and the cholesterol transport blocker, ezetimibe, vs. monotherapy with a statin in HIV-infected patients not achieving lipid goals.MethodsThis was a 12-week, prospective, randomized, open-label clinical trial. Patients were eligible if they had an apolipoprotein B (apoB) >0.80 g/L despite therapy with rosuvastatin 10 mg daily for a minimum of 12 weeks. Patients were randomized to take ezetimibe 10 mg/rosuvastatin 10 mg or rosuvastatin 20 mg for 12 weeks. Percentage and absolute change in apoB (primary outcome), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, apoliporpotein A1 (apoA1), apoB/apoA1, TC/HDL-C, atherogenic index of plasma (API), and high-sensitivity C-reactive protein (hsCRP) were compared. Changes in safety parameters (such as AST, ALT, CK) and clinical symptoms were also assessed.ResultsForty-three patients (23 on ezetimibe 10 mg/rosuvastatin 10 mg and 20 on rosuvastatin 20 mg) completed the trial. Baseline characteristics did not differ between the groups. Significant improvements in apoB were seen with both ezetimibe plus rosuvastatin (mean of -0.17 g/L, p < 0.001) and rosuvastatin 20 mg (mean of -0.13 g/L, p = 0.03) treatment groups, but did not differ between groups (p = 0.53). Significant between-group differences were observed for mean TC (-1.01 mmol/L vs. -0.50 mmol/L, p = 0.03), TG (-0.62 mmol/L vs -0.17 mmol/L, p = 0.03), and non-HDL-C (-0.97 mmol/L vs. -0.53 mmol/L, p = 0.03) all in favour of the ezetimibe plus rosuvastatin group. Two patients, both in the rosuvastatin 20 mg group, experienced mild myalgias; neither discontinued the study.ConclusionsThe addition of ezetimibe to rosuvastatin appears to be safe in patients with HIV. Furthermore, the combination of ezetimibe and rosuvastatin improved TG, AIP and non-HDL cholesterol levels more than a dose increase in rosuvastatin in patients with HIV-associated dyslipidemia.

주제어

참고문헌 (34)

1. Law MG Friis-Moller N El-Sadr WM Weber R Reiss P D'Arminio Monforteet A The use of Framingham equation to predict myocardial infarctions in HIV-infected patient: comparison with observed events in the D:A:D Study HIV Med 2006 7 218 30 10.1111/j.1468-1293.2006.00362.x 16630034

상세보기
2. Triant VA Lee H Hadigan C Grinspoon SK Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease J Clin Endocrinol Metab. 2007 92 2506 12 10.1210/jc.2006-2190 17456578

상세보기
3. Cockerham L Scherzer R Zolopa A Rimland D Lewis CE Bacchetti P Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era J Acquir Immune Defic Syndr. 2010 53 102 6 10.1097/QAI.0b013e3181b79d22 19738484

상세보기
4. Petoumenos K Reiss P Ryom L Rickenbach M Sabin CA El-Sadr W Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations HIV Med 2014 15 10 595 603 24840675
5. Hsue PY Squires K Bolger AF Capili B Mensah GA Temesgen Z Screening and Assessment of Coronary Heart Disease in HIV-Infected Patients Circulation. 2008 118 e41 7 10.1161/CIRCULATIONAHA.107.189626 18566317

상세보기
6. Lichtenstein KA Armon C Buchacz K Chmiel JS Buckner K Tedaldi E Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients Prev Chronic Dis. 2013 10 E10 10.5888/pcd10.120083 23347705

상세보기
7. holesterol Treatment Trialists’ (CTT) Collaboration Baigent C Blackwell L Emberson J Holland LE Reith C Bhala N Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 2010 376 9753 1670 81 10.1016/S0140-6736(10)61350-5 21067804

상세보기
8. Ahmed MH Al-Atta A Hamad MA The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges Expert Opin Pharmacother 2012 13 13 1901 9 10.1517/14656566.2012.706604 22770622

상세보기
9. Dube MP Stein JH Aberg JA Fichtenbaum CJ Gerber JG Tashima KT Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group Clin Infect Dis. 2003 37 613 27 10.1086/378131 12942391

상세보기
10. Couture P Lamarche B Ezetimibe and bile acid sequestrants: impact on lipoprotein metabolism and beyond Curr Opin Lipidol 2013 24 3 227 32 10.1097/MOL.0b013e3283613a55 23571732

상세보기
11. Bennett MT Johns KW Bondy GP Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV Lipids Health Dis. 2007 6 15 10.1186/1476-511X-6-15 17565701

상세보기
12. Berg-Wolf MV Klibanov OM Gaughan JP Tedaldi EM Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients AIDS Patient Care STDS. 2008 22 483 8 10.1089/apc.2007.0206 18462073

상세보기
13. Negredo E Molto J Puig J Cinquegrana D Bonjoch A Perez-Alvarez N Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins AIDS. 2006 20 2159 64 10.1097/01.aids.0000247573.95880.db 17086055

상세보기
14. Chow D Chen HC Glesby MJ Busti A Souza S Andersen J Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV infected patients AIDS 2009 23 16 2133 41 10.1097/QAD.0b013e32833068e3 19770624

상세보기
15. Calza L Colangeli V Manfredi R Legnani G Tampellini L Pocaterra D Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study AIDS. 2005 19 1103 5 10.1097/01.aids.0000174458.86121.43 15958843

상세보기
16. Johns KW Bennett MT Bondy GP Are HIV positive patients resistant to statin therapy? Lipids Health Dis. 2007 6 27 10.1186/1476-511X-6-27 17958912

상세보기
17. Calza L Manfredi R Colangeli V Pocaterra D Pavoni M Chiodo F Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors Curr HIV Res. 2008 6 572 8 10.2174/157016208786501481 18991624
18. Aslangul E Assoumou L Bittar R Valantin MA Kalmykova O Peytavin G Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial AIDS. 2010 24 77 83 10.1097/QAD.0b013e328331d2ab 19838098

상세보기
19. Barter PJ Ballantyne CM Carmena R Castro Cabezas M Chapman MJ Couture P Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel J Intern Med 2006 259 3 247 58 10.1111/j.1365-2796.2006.01616.x 16476102

상세보기
20. Anderson TJ Grégoire J Hegele RA Couture P Mancini GBJ McPherson R 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult Can J Cardiol 2013 29 2 151 67 10.1016/j.cjca.2012.11.032 23351925

상세보기
21. Holmes DT Frohlich J Buhr KA The concept of precision extended to the atherogenic index of plasma Clin Biochem. 2008 41 631 5 10.1016/j.clinbiochem.2008.01.023 18280809

상세보기
22. Sniderman AD Williams K Contois JH Monroe HM McQueen MJ de Graaf J A meta-analysis of lowdensity lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk Circ Cardiovasc Qual Outcomes. 2011 4 337 45 10.1161/CIRCOUTCOMES.110.959247 21487090

상세보기
23. Piconi S Parisotto S Rizzardini G Passerini S Meraviglia P Schiavini M Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals AIDS 2013 27 3 381 9 10.1097/QAD.0b013e32835abcc9 23079800

상세보기
24. Dujovne CA Ettinger MP McNeer JF Lipka LJ LeBeaut AP Suresh R Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia Am J Cardiol. 2002 90 1092 7 10.1016/S0002-9149(02)02798-4 12423709

상세보기
25. Averna M Missault L Vaverkova H Farnier M Viigimaa M Dong Q Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome Diab Vasc Dis Res 2011 8 4 262 70 10.1177/1479164111418136 21859750

상세보기
26. Bottaro EG Caravello O Scapellato PG Stambulian M Vidal GI Loggia V Rosuvastatin for the treatment ofdyslipidemia in HIV-infected patients receiving highly active antiretroviral therapy. Preliminary experience Enferm Infecc Microbiol Clin 2008 26 325 9 10.1157/13123836 18588813

상세보기
27. Walldius G Jungner I Aastveit AH Holme I Furberg CD Sniderman AD The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk Clin Chem Lab Med. 2004 42 1355 63 10.1515/CCLM.2004.254 15576296

상세보기
28. Ding D Li X Qiu J Li R Zhang Y Su D Serum lipids, apolipoproteins, and mortality among Coronary Artery Disease Patients Biomed Res Int 2014 2014 11
29. Coll B Aragones G Parra S Alonso-Villaverde C Masana L Ezetimibe effectively decreases LDLcholesterol in HIV-infected patients AIDS. 2006 20 1675 7 10.1097/01.aids.0000238418.43937.3b 16868453

상세보기
30. Emerging Risk Factors Collaboration Kaptoge S Di Angelantonio E Lowe G Pepys MB Thompson SG C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis Lancet 2010 375 132 40 10.1016/S0140-6736(10)60484-9 20031199

상세보기
31. Ridker PM Danielson E Fonseca FA Genest J Gotto AM Jr Kastelein JJ Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med. 2008 359 2195 207 10.1056/NEJMoa0807646 18997196

상세보기
32. Zacho J Tybjaerg-Hansen A Jensen JS Grande P Sillesen H Nordestgaard BG Genetically elevated C-reactive protein and ischemic vascular disease N Engl J Med. 2008 359 1897 908 10.1056/NEJMoa0707402 18971492

상세보기
33. Dobiasova M Frohlich J The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)) Clin Biochem. 2001 34 583 8 10.1016/S0009-9120(01)00263-6 11738396

상세보기
34. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 2001 285 19 2486 97 10.1001/jama.285.19.2486 11368702

상세보기

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients 원문보기

Abstract ▼ AI-Helper

주제어

참고문헌 (34)

이 논문을 인용한 문헌

관련 콘텐츠

원문 보기

원문 URL 링크

오픈액세스(OA) 유형

연관된 기능

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트